Evidence map›Paper›PMID 28190698›Full record

ReviewEpilepsy & behavior : E&B2017

Therapeutic effects of cannabinoids in animal models of seizures, epilepsy, epileptogenesis, and epilepsy-related neuroprotection.

Evan C Rosenberg, Pabitra H Patra, Benjamin J Whalley

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Epilepsy & behavior : E&B, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 86 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
86citing papers in PubMed, 4 pooled it
15.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

86 citing papers in PubMed, 4 syntheses or guidelines pooled it, 194 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Article
  7. Review
  8. Article
  9. Article
  10. Carvone derived cannabidiol enantiomers as novel anticonvulsants.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2025
    Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article

26 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Evan C RosenbergDepartment of Neuroscience and Physiology, Neuroscience Institute, NYU Langone Medical Center, New York, NY 10016, USA.
Pabitra H PatraDepartment of Pharmacy, School of Chemistry, Food & Nutritional Sciences and Pharmacy, University of Reading, Whiteknights, Reading, Berkshire RG6 6AP, UK.
Benjamin J WhalleyDepartment of Pharmacy, School of Chemistry, Food & Nutritional Sciences and Pharmacy, University of Reading, Whiteknights, Reading, Berkshire RG6 6AP, UK. Electronic address: b.j.whalley@reading.ac.uk.
University of Reading · GBNYU Langone Health · US

Funding

Targeting the LPI-GPR55 pathway to investigate the potential anti-seizure mechanism of cannabidiolF30NS100293 · NINDS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI ROSENBERG, EVAN CORY · 2017 to 2020
$165k
NINDS NIH HHS F30 NS100293
6 · The paper itself

Abstract

The isolation and identification of the discrete plant cannabinoids in marijuana revived interest in analyzing historical therapeutic claims made for cannabis in clinical case studies and anecdotes. In particular, sources as old as the 11th and 15th centuries claimed efficacy for crude marijuana extracts in the treatment of convulsive disorders, prompting a particularly active area of preclinical research into the therapeutic potential of plant cannabinoids in epilepsy. Since that time, a large body of literature has accumulated describing the effects of several of the >100 individual plant cannabinoids in preclinical models of seizures, epilepsy, epileptogenesis, and epilepsy-related neuroprotection. We surveyed the literature for relevant reports of such plant cannabinoid effects and critically reviewed their findings. We found that acute CB

Indexed as

Disease Models, AnimalAnimalsAnticonvulsantsBrainCannabidiolCannabinoidsCannabisDronabinolDrug CombinationsEpilepsyHumansNeuroprotective AgentsReceptor, Cannabinoid, CB1SeizuresAnticonvulsantsCannabidiolCannabinoidsDronabinolDrug CombinationsnabiximolsNeuroprotective AgentsReceptor, Cannabinoid, CB1Animal modelsCannabinoidEpilepsyEpileptogenesisNeuroprotectionSeizure

Identifiers

PMID28190698
PMCPMC5651410
OpenAlexW2587338459

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.